ProMIS Neurosciences Inc PMN

hope

[Gbathat]

Aside from the cheerleading by PMN for aducanumab, and the perhaps worse than anticipated external FDA panel review, I cannot help but think the bad news for aducanumab simply highlights the benefits of and need for PMN310.  

The panel did not make a judgement on the mechanism of action of aducanumab, only on the PHIII data discrepancies.  The trend in the PHIII studies was more benefit at higher doses, but higher dose applications were complicated by the fact that aducanumab is not selective enough for the target, resulting in side effects that impaired health and/or the analysis itself.

PMN310 is a no brainer at this point.  The massive potential market is larger for PMN than it was two weeks ago.  It is still a long way off to that stage, but a PHI announcement on PMN310 would make the stock go through the roof.  By a multiple of at least 20 from current levels, in my opinion.  Not a risk free investment by any means, but I am definitely not bailing and may average down a bit further.

[G1945V]

Gbathat...Exactly right. And so as the 8 million PMN shares that got bought agree with the same sentiment. We just need to wait this out. Not the time to bail out.   glta G1945V   

[retiredcop]

Interesting to see what the European regulators think of the treatment....

[retiredcop]

Biogen has a plan B ,  this is why they are not considering PMN yet.....

[retiredcop]

1. Aducanumab is still in FDA review and may still be approved ; 2. Most importantly, Biogen is collaborating with ESAI on BAN2401, with expected phase 3 readout in 2022.  Ban2401 has a similar, but better profile compared to aducanumab.  It does bind plaque but clinical trials show far less ARIA-E (brain swelling side effect) vs aducanumab (10-20% vs 30-50% on aducanumab). Also, BAN2401

[G1945V]

ProMis does not need Biogen. All PMN needs is the FDA approving the Abeta hypothesis. PMN partners with a competitor to Biogen to fund clinical trial.   G1945V

[retiredcop]

Exactly.....that's whooping  I was ho08ng someone had access to the stat publication..what we could see that the advisory committee actually mentioned that they are only dealing with the Biogen submission...they can't comment or won't comment on the validity of the amyloid science. PMN just needs one large company to decide that the  amyloid approach is worth it...the

[farmerjane]

Most importantly, these comments are all distractions and nonsense. No pharma will take up on Promis because they are waiting for Biogen or Biogen/Esai results is nonsense. Question the science if no takers?

[G1945V]

"Question the science if no takers?" This is why other pharmas are hanging in the balance to see if targetting the amyloid plaques really works. And so is PMN.  https://www.abc.net.au/news/health/2020-11-14/alzheimers-drug-aducanumab-faces-major-setback-with-fda/12881536 "To date, more than 300 Alzheimer's drug trials have failed, including more than 30 phase-3

[farmerjane]

Difference, PMN 310 targeting toxic oligomers, not amyloid plaque. Pharma obviously not buying this theory or they would be all over it, with one of the worlds most unmet medical needs. 

[G1945V]

All fall under the Amyloid Beta Hypothesis  : -Monomers -Plaque -Toxic Oligomers G1945V

[farmerjane]

Cashman, on there website in the news Pharma boardroom posted Nov 4, 2020. Likely AdCom deliberations, "Aducanumab's most meaningful limitiation, however, is that it does not target the real culprit of AD. The drug was originally designed to target amyloid-beta plaque, now believed to be an ineffective drug target for AD. An accumulating body of data has shifted drug development focus to

[G1945V]

"Promis has been saying this for a couple of years, why no takers for the clinic?" Yes, PMN310 shows greater selectivity for toxic oligomers compared to aducanumab. Aducanumab binds to all 3 forms of AB but mostly onto fibrils(plaque) However all this goes to show that the amyloid-beta hypothesis is yet to be proven. I believe Biogen will come close to proving it. It's been my

[farmerjane]

Billions have been spent on alzheimers trials, reasearch but they can't get any takers for pmn310 into the clinic for 15 million? Not buying the Biogen theory, there trial caused all kinds of interest obviously pharma not interested pmn 310, or we would already be in the clinic. Need to clean up there webpage, Homepage Corporate update Nov, 9, 2020 really Septembers with some red lining

[M101]

No takers for 15 million when there's no control on how it's spent. So far we have no evidence that anyone wants to deal with Gene or Elliot. We don't know if it's been a matter of price or product or personality, but we know the end result. 

[M101]

Also, no single entity could provide the 15 million at this price without triggering the shareholder's rights agreement. Mike Biggar controlled 10% for a while so I assume management is still ok with that level and would sell up to 30 million shares tomorrow if it walked in the door. They want the money but not enough to give up any control.   

[M101]

Like it or not, farmerjane has to be mostly right.  "We're like that failure, only better"  does not seem to be opening any doors for Gene.  And who wants to listen to Elliot on the phone?

[retiredcop]

If you know anyone that has a subscription to STAT... we need to see this latest article .. " An FDA adviser on why his panel took a skeptical view on Biogen’s Alzheimer’s drug"  and one other thing.. the research group that worked with the mice was located in Europe (where Biogen is seeking approval)